Refrain From Submitting the Stated Recommendation to HHS to Reclassify Hydrocodone Combination Products That Contain Hydrocodone Bitartrate in a Strength That is Lower Than 5 mg in Strength Into Schedule II
cder citizen petition 2013-10552 open hydrocodone bitartrate 5 mg 7.5 mg 10 mg Schedule II
2017-03-21
FDA-2013-P-1711-0004
04:00:00
https://api.regulations.gov/v4/comments/FDA-2013-P-1711-0004
Anonymous
Anonymous
I represent The Hawaii academy of Physician Assistants, a constituent organization of the AAPA.  We work in a state where PAs are not yet authorized to prescribe Schedule II medications. The Drug Enforcement Administrations (DEAs) proposal (Docket No. DEA-389. ) to reclassify hydrocodone combination products from Schedule III to Schedule II will affect us and the patients we serve. If implemented, the proposed rule will restrict PAs from prescribing hydrocodone combination productions in states where they do not yet have prescribing authority for Schedule II drugs. Reclassifying the medications will impose additional burdens on all patients who need these medications to manage severe pain.We are opposed to this change and request that hydrocodone not be reclassified as a Schedule II drug.Fielding Mercer, PA-CPresidentHawaii Academy of Physician Assistants